Company / Accounts Receivable
TEVA PHARMACEUTICAL INDUSTRIES LTD Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$3.7B
FY2025
5-year range
$3.1B / $4.5B
FY2021-FY2025
Trend
+21.2%
vs FY2024
Sector context
#10 of 115
Health Care
What the data says
Among 115 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the top 9% for accounts receivable. Accounts Receivable returned to growth in FY2025 after 8 years of decline, reaching $3.7B.
Based on SEC 10-K filings.
$3.7B in FY2025 with a 5-year CAGR of -4.1%. Top quartile in the Health Care sector.
Improved from $3.4B to $3.7B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +0.1%
- 5-Year CAGR
- -4.1%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 115This company $3.7B Sector average $1.1B
▼
+231.9% above sector average
Key checks
Key Insights
- 5-year CAGR of -4.1%, indicating a declining trend.
- In FY2025, accounts receivable increased 21.2% year-over-year.
- Ranks #10 out of 115 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.7B | +21.2% |
| FY2024 | $3.1B | -10.2% |
| FY2023 | $3.4B | -7.8% |
| FY2022 | $3.7B | -18.4% |
| FY2021 | $4.5B | -1.1% |
| FY2020 | $4.6B | -19.3% |
| FY2019 | $5.7B | -2.5% |
| FY2018 | $5.8B | -18.3% |
| FY2017 | $7.1B | -5.3% |
| FY2016 | $7.5B | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026